New York, NY -- (SBWIRE) -- 12/10/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: ReneSola Ltd. (ADR) (NYSE:SOL), Dendreon Corporation (NASDAQ:DNDN), Cisco Systems, Inc (NASDAQ:CSCO), WORLDWIDE INTERNET (OTCMKTS:WNTR)
ReneSola Ltd. (ADR) (NYSE:SOL) the stock opened the session at $2.96 but then moved to $2.99. At that price, the stock showed a negative performance of -0.99%. ReneSola Ltd (ReneSola), incorporated on March 17, 2006, is a global manufacturer of solar wafers and producer of solar power products based in the People's Republic of China. ReneSola possess a global network of suppliers and customers that includes some of the global manufacturers of solar cells and modules. As of December 31, 2012, the Company had an annual wafer manufacturing capacity of approximately 2,000 megawatts, consisting of monocrystalline wafer manufacturing capacity of approximately 400 megawatts and multicrystalline wafer manufacturing capacity of approximately 1,800 megawatts. In July 2012, it sold 5.95 megawatt of its Virtus modules to Solargain PV Pty Ltd. In October 2012, it established a Japanese subsidiary, ReneSola Japan Ltd. In 2013,
Will SOL Get Buyers Even After The Recent Rally? Find Out Here
Dendreon Corporation (NASDAQ:DNDN) opened the session at $3.00 and closed the session at $3.00. The stock showed a negative performance of -0.33% in previous trading session. Traded with volume of 2.16 million shares in the prior session and the average volume of the stock remained 4.30 million shares. Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may significantly improve cancer treatment options for patients. The Company's product portfolio includes active cellular immunotherapies and a small molecule product candidate that could be applicable to treating multiple types of cancers. PROVENGE (sipuleucel-T), is the Company's first commercialized product approved by the United States Food and Drug Administration (FDA), and is a autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic, castrate-resistant (hormone-refractory) prostate cancer.
Has DNDN Found The Bottom And Ready To Gain Momentum? Find Out Here
Cisco Systems, Inc (NASDAQ:CSCO) opened the session at $21.30 and closed the session at $21.22. The stock showed a negative performance of -0.28% in previous trading session. The beta of the stock remained 1.26. Cisco Systems, Inc. (Cisco) designs, manufactures, and sells Internet protocol (IP)-based networking and other products related to the communications and information technology (IT) industry and provide services associated with these products and their use. The Company provides a line of products for transporting data, voice, and video within buildings, across campuses, and worldwide. Its products are designed to transform how people connect, communicate, and collaborate.
Why Should Investors Buy CSCO After the Recent Fall? Just Go Here and Find Out
WORLDWIDE INTERNET (OTCMKTS:WNTR) the stock advanced 24.19% and finished the session at $0.0077. Traded with volume of 26.31 million shares in the prior session and the average volume of the stock remained 10.96 million shares. The beta of the stock remained 0.39.
Will WNTR Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)